enavatuzumab (PDL192) / AbbVie - LARVOL DELTA

Bioinformatics analysis of key genes and potential therapeutic agents for vascular calcification in chronic kidney disease. (PubMed, Nucleosides Nucleotides Nucleic Acids) - "Most notably, the top five potential therapeutic drugs-ENAVATUZUMAB, DENOSUMAB, ALICAFORSEN, BI-505, and ENLIMOMAB PEGOL-were identified for vascular calcification in CKD. However, further molecular biological experiments are required to confirm these findings."

Journal • Chronic Kidney Disease • Nephrology • Renal Disease • ICAM1 • TNFRSF11A • TNFRSF12A • TNFRSF25 • TNFSF11

Single-cell RNA sequencing and spatial transcriptomics of bladder Ewing sarcoma. (PubMed, iScience) - "In addition, Enavatuzumab can significantly inhibit the migratory ability of the Ewing sarcoma cell line RD-ES. This groundbreaking study provides unprecedented mechanistic insights into the progression of bladder ES/PNET and introduces a potential therapeutic avenue for treating this challenging malignancy."

Journal • Bladder Cancer • Embryonal Tumor • Ewing Sarcoma • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer • TNFRSF12A • TNFRSF25 • TNFSF12

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov) - P1 | N=7 | Terminated | Sponsor: Yale University | N=24 ➔ 7 | Trial completion date: Jun 2024 ➔ Jan 2024 | Recruiting ➔ Terminated | Trial primary completion date: Jun 2024 ➔ Jan 2024; PI changed institutions

Enrollment change • Trial completion date • Trial primary completion date • Trial termination • Head and Neck Cancer • Lung Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Antibody-based soluble and membrane-bound TWEAK mimicking agonists with FcγR-independent activity. (PubMed, Front Immunol) - "Noteworthy, activation of the classical NFκB pathway, which naturally is predominately triggered by membrane-bound TWEAK but not soluble TWEAK, was preferentially observed with a subset of constructs containing Fn14 binding sites at opposing sites of the IgG scaffold, e.g. IgG1-scFv fusion proteins. A superior ability of IgG1-scFv fusion proteins to trigger classical NFκB signaling was also observed with the anti-Fn14 antibody PDL192 suggesting that we identified generic structures for Fn14 antibody variants mimicking soluble and membrane-bound TWEAK."

Journal • Solid Tumor • TNFA

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov) - P1 | N=24 | Recruiting | Sponsor: Yale University | Not yet recruiting ➔ Recruiting | Initiation date: Nov 2022 ➔ Feb 2023

Enrollment open • Trial initiation date • Head and Neck Cancer • Immunology • Lung Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Yale University | Initiation date: Aug 2022 ➔ Nov 2022

Trial initiation date • Head and Neck Cancer • Immunology • Lung Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Non-invasive Measurement of PD-L1 Levels With Positron Emission Tomography (PET) in Head and Neck Malignancies and Intracranial Metastases (clinicaltrials.gov) - P1 | N=24 | Not yet recruiting | Sponsor: Yale University

New P1 trial • Head and Neck Cancer • Immunology • Lung Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma of Head and Neck • PD-L1

Anti-Fn14 Antibody-Conjugated Nanoparticles Display Membrane TWEAK-Like Agonism. (PubMed, Pharmaceutics) - "We found that Fn14 binding of the anti-Fn14 antibodies PDL192 and 5B6 is preserved upon attachment to the nanoparticles. More importantly, the gold nanoparticle-presented anti-Fn14 antibody molecules displayed strong agonistic activity. Our results suggest that conjugation of monoclonal anti-TNFR antibodies to gold nanoparticles can be exploited to uncover their latent agonism, e.g., for immunotherapeutic applications."

Journal